Results 241 to 250 of about 2,878,819 (307)

Correction to: Structure and function of therapeutic antibodies approved by the US FDA in 2024. [PDF]

Antib Ther
europepmc   +1 more source

Discovery of Therapeutic Antibodies Targeting Complex Multi-Spanning Membrane Proteins. [PDF]

BioDrugs
Stephens AD, Wilkinson T.
europepmc   +1 more source

Type I interferons modulate autophagy to shape gemcitabine response in pancreatic cancer cells

FEBS Open Bio, EarlyView.
Type I interferons differentially modulate autophagy and the response of pancreatic cancer cells to gemcitabine. IFNα2b stimulates autophagic flux and protects cells from gemcitabine‐induced cell death, contributing to chemoresistance. In contrast, IFNβ1a inhibits autophagosome formation and enhances gemcitabine‐induced cell death, resulting in ...
Lucy E. Bonilla, Martín M. Ledesma, Santiago A. Behr, Matías A. Pibuel, María L. Palanek, Daniel H. Grasso, Maria N. Garcia, Juan Garona, Silvina L. Lompardía, Elida Álvarez, Daniela L. Papademetrio   +10 more
wiley   +1 more source

Internalization of therapeutic antibodies into dendritic cells as a risk factor for immunogenicity. [PDF]

Front Immunol
Siegel M, Bolender AL, Ducret A, Fraidling J, Hartman K, Looney CM, Rohr O, Hickling TP, Kettenberger H, Lechmann M, Marban-Doran C, Kraft TE.   +11 more
europepmc   +1 more source

Selective elimination of quiescent cancer cells by dequalinium chloride via ROS‐mediated ferroptosis

FEBS Open Bio, EarlyView.
Dequalinium chloride (DQ) selectively eliminates quiescent cancer cells (QCCs) by amplifying mitochondrial ROS. QCCs exhibit elevated basal ROS and limited redox‐buffering capacity, making them vulnerable to further ROS increases. DQ‐induced ROS exceeds the tolerance threshold, triggering lipid peroxidation and ferroptosis, whereas proliferating cells ...
Kotaro Miyamoto, Shiori Sakai, Minori Endo, Terigele, Mizuho Niibori, Taiki Morita, Yu Goto, Arisa Yoshida, Tomohiro Tanaka, Ning Lin, Takahiro Kuchimaru, Hiroyuki Nakamura, Masahiro Inoue, Shinae Kizaka‐Kondoh, Tetsuya Kadonosono   +14 more
wiley   +1 more source

Challenges and Insights in Absolute Quantification of Recombinant Therapeutic Antibodies by Mass Spectrometry: An Introductory Review. [PDF]

Antibodies (Basel)
Döring S, Weller MG, Reinders Y, Konthur Z, Jaeger C.   +4 more
europepmc   +1 more source

TRPML1 agonist ML‐SA5 attenuates pulmonary fibroblast activation by suppressing mTOR and restoring autophagic flux

FEBS Open Bio, EarlyView.
TGF‐β1 stimulation downregulates lysosomal channel TRPML1 in pulmonary fibroblasts. The TRPML1 agonist ML‐SA5 suppressed fibroblast‐to‐myofibroblast activation and collagen production. Mechanistically, ML‐SA5 inhibited mTOR phosphorylation, restored autophagic flux, and its effects were enhanced by rapamycin (mTOR inhibitor) and reversed by MHY1485 ...
Jiatong Yao, Xiaoting Kang, Lulu Meng, Shaoxuan Zhang, Qiujie Li, Jinyu Zhou, Mengyue Xue, Chu Li, Hua Zhu, Pengzhou Hang, Jing Zhao   +10 more
wiley   +1 more source

Stable and reusable calcium-responsive biopolymer for affinity precipitation of therapeutic antibodies. [PDF]

Protein Sci
Park H, Oh JS, Lee J, Bang J, Park K, Jeong S, Park S, Woo JS, Kim S.   +8 more
europepmc   +1 more source

Therapeutic Antibodies [PDF]

, 2008
openaire   +1 more source

Unraveling the dynamics of B7-H3-targeting therapeutic antibodies in cancer through PET imaging and antibody pharmacokinetics. [PDF]

J Control Release
Fernandes B, Olkowski CP, Ghaemi B, Basuli F, Shi J, Kiesewetter DO, Lang L, Elijah E, Swenson R, Choyke PL, Lin FI, Jacobson O.   +11 more
europepmc   +1 more source